Targeting Activated Lymphocytes With Photodynamic Therapy: Susceptibility of Mitogen‐stimulated Splenic Lymphocytes to Benzoporphyrin Derivative (Bpd) Photosensitization

Abstract

Benzoporphyrin derivative monoacid ring A (BPD), a hydrophobic chlorin-like porphyrin derivative, which fluoresces strongly at 690 nm, may have potential for both oncologic and nononcologic applications in photodynamic therapy (PDT). To study the influence of cellular characteristics on the uptake of BPD, the murine tumor cell line (P815), and in vitro and in vivo concanavalin A (Con A) -stimulated and unstimulated murine splenic lymphocytes were incubated with 2 micrograms/mL BPD at 37 degrees C for 0-60 min. At various times, cells were lysed and the amount of BPD taken up by cells was quantified by fluorescence measurements. The subsets of cells taking up BPD were analyzed using a panel of monoclonal antibodies and the Coulter XL fluorescence-activated cell sorter. Furthermore, Con A-stimulated and unstimulated spleen cells were incubated with 0-50 ng/mliter of BPD for 1 h prior to exposure to red light (7.2 J/cm2). Cell survival 24 h post-PDT was measured by the MTT assay. We found that the rapidly dividing tumor cell line and mitogen-stimulated murine T cells (mainly CD4+/IL-2R+) took up significantly more BPD (5-10-fold) than do unstimulated splenic lymphocytes. Increased BPD uptake correlated with greater photoinactivation when these cells were exposed to light at a wavelength of 690 nm. These findings suggest that activated cells of the immune system may be a target for photoinactivation by BPD.

Uptake of Verteporfin® by articular tissues following systemic and intra-articular administration

“…Cellular activation affords additional selectivity in therapy to pathogenic tissues; activated cells have been shown to take up BPD-MA to a greater extent than quiescent populations, resulting in greater sensitivity to PDT [14]. We have shown in rabbit synovium, that inflammatory cells bearing the MHC-class II activation marker demonstrated greater uptake of BPD [9].…”

Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity

“…Numerous studies have documented that photosensitisers efficiently accumulate in normal human lymphocytes [105,106]. However, resting lymphocytes only poorly accumulate photosensitisers, and the uptake is improved in activated cells [106][107][108]. PDT of resting T-cells leads to MHC class I molecule's downregulation.…”

Experimental photodynamic laser therapy for rheumatoid arthritis with a second generation photosensitizer

“…A prototype with up to 1.0 W was employed in the present study. Up to 99% of the BPD-MA is excreted within 72 h; no substantial side effects have yet been described [18]. For treating the macula degeneration of the eye, which is performed as a clinical phase II trial with an identical dose prophylactic, only wearing of dark glasses for 7 days is recommended.…”